Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Healthy
Interventions
DRUG

Lofexidine

All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.

DRUG

Paroxetine

All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

USWM, LLC (dba US WorldMeds)

INDUSTRY

NCT02681198 - Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers | Biotech Hunter | Biotech Hunter